|
| Friday, March 7, 2025 |
|
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its annual results for the year ended December 31, 2024 (the 'Year'), reporting record-high revenue and healthy net profit despite the challenging business landscape. more info >> |
|
| Friday, August 16, 2024 |
|
|
OrbusNeich Records Net Profit of US$18.8 Million for the First Half of 2024 |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its interim results for the six months ended June 30, 2024 (the 'Reporting Period), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges. more info >> |
|
| Wednesday, April 24, 2024 |
|
|
OrbusNeich's Joint Venture Kicks Off TricValve Clinical Trial in Mainland China |
| OrbusNeich Medical Group Holdings Limited announced today that the Group's joint venture OrbusNeich P+F Company Limited ("ON P&F") has commenced the clinical trial for the TricValve Transcatheter Bicaval Valve System ("TricValve"), to treat patients with hemodynamically relevant tricuspid insufficiency and caval reflux, on April 22, 2024 across Mainland China. more info >> |
|
| Thursday, March 7, 2024 |
|
|
OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Monday, November 27, 2023 |
|
|
OrbusNeich Acquires 84% Stake in Indonesian Distributor PT Revass for Approximately US$15 Million |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich", 6929.HK), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Thursday, November 23, 2023 |
|
|
OrbusNeich Adds Drug-eluting Balloons in Product Portfolio Through Acquisition of Eucatech AG |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Thursday, August 17, 2023 |
|
|
OrbusNeich FY2023 Interim Net Profit Triples to US$25.2 Million, Total Revenue Increases by 18.2% to US$81.4 Million |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today announced its interim results for the six months ended 30 June 2023, reporting growth in both revenue and net profit. more info >> |
|
| Monday, May 8, 2023 |
|
|
OrbusNeich Kicks Off Clinical Study of Scoreflex TRIO, Completing China's First PCI Intervention Procedure with High-Pressure, Three-wire Scoring Balloon Dilatation Catheter |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Tuesday, March 28, 2023 |
|
|
OrbusNeich Plans to Set up Its Largest R&D and Production Base in Fuchun Bay New Town, Hangzhou, the PRC |
| OrbusNeich Medical (Zhejiang) Company Limited ("OrbusNeich Zhejiang"), a wholly-owned subsidiary of OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Wednesday, March 8, 2023 |
|
|
OrbusNeich Announces First Annual Results After Listing, Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
|
|
